TW201817731A - ［２－（１－甲基－１ｈ－吡唑－４－基）－６－（ 啉－４－基）－９ｈ－嘌呤－８－基］［４－（ 啉－４－基）哌啶－１－基］甲酮及其製藥上容許鹽之結晶 - Google Patents

［２－（１－甲基－１ｈ－吡唑－４－基）－６－（ 啉－４－基）－９ｈ－嘌呤－８－基］［４－（ 啉－４－基）哌啶－１－基］甲酮及其製藥上容許鹽之結晶 Download PDF

Info

Publication number
TW201817731A
TW201817731A TW106133296A TW106133296A TW201817731A TW 201817731 A TW201817731 A TW 201817731A TW 106133296 A TW106133296 A TW 106133296A TW 106133296 A TW106133296 A TW 106133296A TW 201817731 A TW201817731 A TW 201817731A
Authority
TW
Taiwan
Prior art keywords
crystals
powder
ray diffraction
crystallization
crystal
Prior art date
Application number
TW106133296A
Other languages
English (en)
Chinese (zh)
Inventor
上田保志
沙加拉姆達斯 阿梅爾
馬朱納斯葛賓德 波比
Original Assignee
日商第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商第一三共股份有限公司 filed Critical 日商第一三共股份有限公司
Publication of TW201817731A publication Critical patent/TW201817731A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW106133296A 2016-09-29 2017-09-28 ［２－（１－甲基－１ｈ－吡唑－４－基）－６－（ 啉－４－基）－９ｈ－嘌呤－８－基］［４－（ 啉－４－基）哌啶－１－基］甲酮及其製藥上容許鹽之結晶 TW201817731A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191168 2016-09-29
JP2016-191168 2016-09-29

Publications (1)

Publication Number Publication Date
TW201817731A true TW201817731A (zh) 2018-05-16

Family

ID=61762818

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106133296A TW201817731A (zh) 2016-09-29 2017-09-28 ［２－（１－甲基－１ｈ－吡唑－４－基）－６－（ 啉－４－基）－９ｈ－嘌呤－８－基］［４－（ 啉－４－基）哌啶－１－基］甲酮及其製藥上容許鹽之結晶

Country Status (5)

Country Link
US (1) US10822336B2 (fr)
EP (1) EP3521290A4 (fr)
JP (1) JPWO2018062382A1 (fr)
TW (1) TW201817731A (fr)
WO (1) WO2018062382A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
JP2011521968A (ja) * 2008-05-30 2011-07-28 ジェネンテック， インコーポレイテッド プリンｐｉ３ｋ阻害剤化合物および使用方法
CA2761445A1 (fr) * 2009-05-27 2010-12-02 Genentech, Inc. Composes pyrimidines bicycliques inhibiteurs de pi3k selectifs pour p110 delta, et procedes d'utilisation
EP2557923A4 (fr) 2010-04-16 2013-10-23 Curis Inc Traitement de cancers présentant des mutations k-ras
ES2536780T3 (es) * 2010-07-14 2015-05-28 F. Hoffmann-La Roche Ag Compuestos de purina selectivos para I3 p110 delta, y métodos de uso
AU2015268776B2 (en) 2010-12-16 2017-04-13 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
CA2820078C (fr) * 2010-12-16 2019-02-12 F. Hoffmann-La Roche Ag Composes tricycliques inhibiteurs de pi3k et procedes d'utilisation
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
CA2980517C (fr) * 2015-03-30 2020-02-25 Daiichi Sankyo Company, Limited Derives de la 6-morpholinyl-2-pyrazolyl-9h-purine et leur utilisation en tant qu'inhibiteurs de la pi3k

Also Published As

Publication number Publication date
JPWO2018062382A1 (ja) 2019-07-11
US20190225614A1 (en) 2019-07-25
US10822336B2 (en) 2020-11-03
WO2018062382A1 (fr) 2018-04-05
EP3521290A4 (fr) 2020-04-22
EP3521290A1 (fr) 2019-08-07

Similar Documents

Publication Publication Date Title
BR112019013017A2 (pt) compostos de éster alifático antiviral de tenofovir ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e uso dos mesmos
JP6402179B2 (ja) 新規な、ＮＩＫ阻害剤としての１−（４−ピリミジニル）−１Ｈ−ピロロ［３，２−ｃ］ピリジン誘導体
EP2989101B1 (fr) Dérivés de 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1h-pyrrolo[2,3-c]pyridine comme inhibiteurs de la nik pour le traitement du cancer
KR102523405B1 (ko) Ｎｉｋ 억제제로서의 신규 피라졸로피리미딘 유도체
KR102524622B1 (ko) Ｎｉｋ 억제제로서의 신규 티에노피리미딘 유도체
TW201336497A (zh) 噻唑啶二酮化合物之結晶型及其製法
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
CN109851638B (zh) 取代的二氨基嘧啶化合物
EP3216790B1 (fr) Forme cristalline de bisulfate inhibiteur de kinase jak et procédé de préparation correspondant
TWI689508B (zh) 可作爲ｐｉ３ｋ抑制劑之吡唑衍生物及其用途
WO2022130304A1 (fr) Cocristal d'un inhibiteur de cdk
JP2022521491A (ja) タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤
US10280174B2 (en) Salt of fused pyrimidine compound and crystal thereof
TW201817731A (zh) ［２－（１－甲基－１ｈ－吡唑－４－基）－６－（ 啉－４－基）－９ｈ－嘌呤－８－基］［４－（ 啉－４－基）哌啶－１－基］甲酮及其製藥上容許鹽之結晶
US12076320B2 (en) Diarylpyrazole compound, composition comprising same, and use thereof
ES2935647T3 (es) Formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il) piridin-3-il)1h-imidazol-2-carboxamida
WO2024208265A1 (fr) Forme de sel et forme cristalline d'un composé hétérocyclique chiral ayant une activité antagoniste de la voie hedgehog
TW202313612A (zh) 腺苷ａｂ受體拮抗劑的固體形式
WO2020043078A1 (fr) Forme de sel et forme cristalline d'un nouveau composé azatricyclique et utilisation associée
CN112851580A (zh) 乐伐替尼甲磺酸盐的晶型及其方法